IPW

Docket No.: 28967/34891.1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/774,802 Confirmation No.: 9059

Filed: February 9, 2004 Art Unit: 1646

For: ALT4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Copies of the references on the PTO/SB/08 are not provided since they were provided in related Application No. 09/169,079.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 28967/34891.1. A duplicate copy of this paper is enclosed.

Dated: November 4, 2004

Respectfully submitted,

By 

Eric M. Brusca
Registration No.: 52,664
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	4,543,439	09/24/85	Fracketton, Jr. et al.	
	A2	4,652,639	03/24/87	Stabinsky	
	A3	4,933,294	06/12/90	Waterfield et al.	
	A4	5,183,884	02/02/93	Kraus et al.	
	A5	5,185,438	02/09/93	Lemischka	
	A6	5,198,359	03/30/93	Tanigucki et al.	
	A7	5,231,001	07/27/93	Kaplan et al.	
	A8	5,256,766	10/26/93	Coughlin	
	A9	5,270,458	12/14/93	Lemischka	
	A10	5,283,354	02/01/94	Lemischka	
	A11	5,367,057	11/22/94	Lemischka	
	A12	5,635,177	06/03/97	Bennett et al.	
	A13	5,643,759	07/01/97	Pfreundschuh, M.	
	A14	5,693,762	12/02/97	Queen, C.L. et al.	
	A15	5,700,822	12/23/97	Hirth, K.P. et al.	
	A16	5,712,395	01/27/98	App, H. et al.	
	A17	5,747,651	05/05/98	Lemischka, I.R.	
	A18	5,750,078	05/12/98	Shitara, K. et al.	
	A19	5,763,441	06/09/98	App, H. et al.	
	A20	5,763,733	06/09/98	Whitlow, M. et al.	
	A21	5,776,427	07/07/98	Thorpe, P.E. et al.	
	A22	5,776,755	07/07/98	Alitalo, K. et al.	
	A23	5,798,097	08/25/98	McKenzie, I.F.C. et al.	
	A24	5,807,548	09/15/98	Shitara, K. et al.	
	A25	5,952,199	09/14/99	Davis-Smyth et al.	
	A26	6,011,003	01/04/00	Charnock-Jones et al.	
	A27	6,331,302	12/18/01	Bennett, et al.	
	A28	6,451,764	09/17/02	Lee, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B1	EP 0 325 224 A2	07/26/89			
	B2	WO 90/14425	11/29/90			
	B3	WO 92/13867	08/20/92			
	B4	WO 92/14748	03/09/92			
	B5	WO 93/14124	07/22/93			
	B6	WO 93/15201	08/05/93			
	B7	WO 94/10202	05/11/94			
	B8	WO 95/24473	09/14/95			
	B9	WO 95/33772	12/14/95			
	B10	WO 96/39515	12/12/96			
	B11	WO 97/05250	02/13/97			
	B12	WO 97/09427	03/13/97			
	B13	WO 98/33917	08/06/98			

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	B14	WO 98/07832	02/26/98				
	B15	WO 99/33485	07/08/99				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C1	Achen, M.G. *et al.*, "Vascular endothelial growth factor D (VEGF-F) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," *Proc. Natl. Acad. Sci., USA, 95(2)*:548-553 (January, 1998).	
	C2	Achen, M.G. *et al.*, "Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3," *Eur. J. Biochem, 267(9)*:2505-15 (May, 2000).	
	C3	Andersson *et al.*, "Structural and Functional Markers During Induced Differentiation in Human Leukemia Cell Lines," *In* R. F. Revoltella *(ed.), Expression of Differentiated Functions in Cancer Cells.* 239-245, Raven Press, New York (1982).	
	C4	Andre, T., *et al.*, "Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FL the neoplastic progression of human colonic mucosa," *Int. J. Cancer, 86(2)*:174-81 (April 15, 2000).	
	C5	Akagi, K., *et al.*, "Vascular endothelial growth factor-C (VEGF-C) expression in colorectal cancer tissues," *Br. J. Cancer, 83(7)*:887-91 (October, 2000).	
	C6	Aprelikova *et al.*, "FLT4, A Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter," *Cancer Research*, 52(3):746-748 (February 1, 1992).	
	C7	Aujame, L. *et al.*, "High affinity human antibodies by phage display," *Human Antibodies, 8(4)*:155-168 (1997).	
	C8	Beckstead, J.H. *et al.*, "Evidence for the Origin of Kaposi's Sarcoma From Lymphatic Endothelium," *Am. J. Pathol., 119(2)*:294-300 (May, 1985).	
	C9	Beers and Berkow eds. The Merck Manual of Diagnosis and Thereapy, Seventeenth Edition, pages 986-995, Merck & Co., Inc. Whitehouse Station, N.J., 1999.	
	C10	Berridge *et al.*, "Cell-Lineage Antigens of the Stem Cell-Megakaryocyte-Platelet Linkage are Associated with the Platelet IIb-IIIa Glycoprotein Complex," *Blood, 66(1)*:76-85 (July, 1985).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/774,802
				Filing Date	February 9, 2004
				First Named Inventor	Kari Alitalo et al.
(Use as many sheets as necessary)				Art Unit	1646
				Examiner Name	To be Assigned
Sheet	3	of	18	Attorney Docket Number	28967/34891.1

	C11	Bolen, J.B., "Nonreceptor Tyrosine Protein Kinases," *Oncogene, 8*:2025-2031 (1993).	
	C12	Bolhuis, R.L. *et al.*, "T cell targeting in cancer therapy," *Cancer Immunology Immunotherapy, 34(1)*:1-8 (1991).	
	C13	Borg *et al.*, "Biochemical Characterization of Two Isoforms of FLT4, a VEGF Receptor-Related Tyrosin Kinase," *Oncogene, 10*:973-984 (1995).	
	C14	Brown, L.F. *et al.*, "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer," *Human Pathology, 26(1)*:86-91 (January, 1995).	
	C15	Brüggemann, M. *et al.*, "Production of human antibody repertoires in transgenic mice," *Curr. Opin. Biotechnol., 8*:455-458 (1997).	
	C16	Brüggemann, M. *et al.*, "Strategies for expressing human antibody repertoires in transgenic mice," *Immunol. Today, 17(8)*:391-397 (August, 1996).	
	C17	Bunone, G., *et al.*, "Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features," *Am. J. Pathol, 155(6)*:1967-76 (December 1999).	
	C18	Cantley *et al.*, "Oncogenes and Signal Transduction," *Cell, 64*:281-302 (January 25, 1991).	
	C19	Cao, Y., *et al.*, "Vascular endothelial growth factor C induces angiogenesis *in vivo*," *Proc. Natl. Acad. Sci. USA, 95*:14389-94 (November 1998).	
	C20	Carter, P. *et al.*, "Toward the Production of Bispecific Antibody Fragments for Clinical Applications," *Journal of Hematotherapy, 4*:463-470 (1995).	
	C21	Catoretti *et al.*, "Monoclonal Antibodies Against Recombinant Parts of the Ki-67 Antigen (MIB 1 and MIB 3) Detect Proliferating Cells in Microwave-Processed Formalin-Fixed Paraffin Section," *J. of Pathol., 168*:357-363 (1992).	
	C22	Cheng & Flanagan, "Identification and Cloning of ELF-1, a Developmentally Expressed Ligand for the Mek4 and Sek Receptor Tyrosine Kinases," *Cell, 79*:157-168 (October 7, 1994).	
	C23	Cole *et al.*, "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," *Monoclonal Antibodies and Cancer Therapy,* Alan R Liss, Inc., pp. 77-96 (1985).	
	C24	Collins *et al.*, "Continuous Growth and Differentiation of Human Myeloid Leukaemic Cells in Suspension Culture," *Nature, 270*:347-349 (1977).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/774,802
				Filing Date	February 9, 2004
				First Named Inventor	Kari Alitalo et al.
(Use as many sheets as necessary)				Art Unit	1646
				Examiner Name	To be Assigned
Sheet	4	of	18	Attorney Docket Number	28967/34891.1

	C25	De Gast, G.C. *et al.*, "Clinical perspectives of bispecific antibodies in cancer," *Cancer Immunol Immunother, 45*:121-123 (1997).	
	C26	De Vries *et al.*, "The *fms*-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," *Science, 255*:989-991 (February 21, 1992).	
	C27	De Waal, R. *et al.*, "Technical Advance: Lack of Lymphangiogenesis in Human Primary Cutaneous Melanoma," *American Journal of Pathology, 150(6)*:1951-1957 (June, 1997).	
	C28	Devereux *et al.*, "A Comprehensive Set of Sequence Analysis Programs for the VAX," *Nucleic Acids Res., 12(1)*:387-395 (1984).	
	C29	Dias, *et al.*, "Vascular endothelial growth factor (VEGF)-C signaling through FLt-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," *Blood*, 99:2179-2184 (2002)	
	C30	Dictor, M. *et al.*, "Lymphaticovenous Differentiation in Kaposi's Sarcoma: Cellular Phenotypes by Stage," *American Journal of Pathology, 130(2)*:411-417 (February, 1988).	
	C31	Edgell *et al.*, "Permanent Cell Line Expressing Human Factor VIII-Related Antigen Established by Hybridization," *Proc. Nat'l. Acad. Sci. USA, 50*:3734-3737 (June, 1983).	
	C32	Eggert, A., *et al.*, "High-Level Expression of Angiogenic Factors Is Associated with Advanced Tumor Stage in Human Neuroblastomas," *Clin. Cancer Res., 6(5)*:1900-8 (May 2000).	
	C33	Eichmann *et al.*, "Molecular cloning of Quek 1 and 2, two quail vascular endothelial growth factor (VEGF) receptor-like molecules," *Gene, 174(1)*:3-8 (1996).	
	C34	Enholm, B. *et al.*, "Vascular Endothelial Growth Factor-C, a Growth Factor for Lymphatic and Blood Vascular Endothelial Cells," *TCM, 8(7)*:292-297 (1998).	
	C35	Fanger, M.W. *et al.*, "Bispecific Antibodies," *Critical Reviews in Immunology, 12(3,4)*:101-124 (1992).	
	C36	Ferrara, N. *et al.*, "The Biology of Vascular Endothelial Growth Factor," *Endocrine Reviews, 18(1)*:4-25 (1997).	
	C37	Fellmer, P.T., *et al.*, "Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas," *Surgery, 126(6)*:1056-61 (December 1999).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	C38	Fielder W., *et al.*, "Expression of FLT4 and its ligand VEGF-C in Acute Myeloid Leukemia," *Leukemia*, 8:1234-7 (August 1997) (Abstract).	
	C39	Finnerty *et al.*, "Molecular Cloning g of Murine FLT and FLT4," *Oncogene, 8(11)*:2293-2298 (1993).	
	C40	Flanagan & Leder, "The *kit* Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts," *Cell, 63*:185-194 (October 5, 1990).	
	C41	Folkman *et al.*, "Long-term culture of capillary endothelial cells," *Proc. Nat'l Acad. Sci., USA, 76(10)*:5217-5221 (October, 1979).	
	C42	Folpe, A.L., *et al.*, "Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3): A Marker of Vascular Tumors with Presumed Lymphatic Differentiation, Including Kaposi's Sarcoma, Kaposiform and Dabska-Type Hemangioendotheliomas, and a Subset of Angiosarcomas," *Mod. Pathol, 13(2)*:180-185 (2000).	
	C43	Foote, J. *et al.*, "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," *J. Mol. Biol., 224*:487-499 (1992).	
	C44	Fortkamp *et al.*, "Cloning and Expression in *Escherichia coli* of a Synthetic DNA for Hirudin, the Blood Coagulation Inhibitor in the Leech," *DNA, 5(6)*:511-517 (1986).	
	C45	Fournier *et al.*, "Mutation at Tyrosine Residue 1337 Abrogates Ligand-Dependent Transforming Capacity of the FLT4 Receptor," *Oncogene, 11*:921-931 (1995).	
	C46	Fournier *et al.*, "Interaction with the Phosphotyrosine Binding Domain/Phosphotyrosine Interacting Domain of SHC Is Required for the Transforming Activity of the FLT4/VEGFR3 Receptor Tyrosine Kinase," *J. Biological Chemistry, 271(22)*:12956-12963 (1996).	
	C47	Gahmberg *et al.*, "Membrane Glycolysation During Cell Differentiation," *In* L. C. Andersson, *et al. (ed.), Gene Expression During Normal and Malignant Differentiation,* 107-123, Academic Press, London (1985).	
	C48	Galland *et al.*, "Chromosomal Localization of FLT4, a Novel Receptor-Type Tyrosine Kinase Gene," *Genomics, 13*:475-478 (1992).	
	C49	Galland *et al.*, "The FLT4 Gene Encodes a Transmembrane Tyrosine Kinase Related to the Vascular Endothelial Growth Factor Receptor," *Oncogene, 8(11)*:1233-1240 (1993).	
	C50	Gasparini, G. *et al.*, "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool," *Journal of Clinical Oncology, 13(3)*:765-782 (March, 1995).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/774,802
				Filing Date	February 9, 2004
				First Named Inventor	Kari Alitalo et al.
(Use as many sheets as necessary)				Art Unit	1646
				Examiner Name	To be Assigned
Sheet	6	of	18	Attorney Docket Number	28967/34891.1

	C51	Genbank Accession X51602 Human flt mRNA for receptor-related tyrosine kinase, deposited by Shibuya, M.	
	C52	Genbank Accession X60280 plasmid pLTRpoly, deposited by Maekelae *et al.*	
	C53	Genbank Accession X68203 H. sapiens mRNA for FLT4, Class III receptor tyrosine kinase, deposited by Aprelikova, O.	
	C54	Genbank Accession X83287 C. coturnix Quek2 mRNA for vascular endothelial growth factor receptor, deposited by Eichmann, *et al.*	
	C55	GenBank Accession No. AJ000185, Homo Sapiens mRNA for vascular endothelial growth factor-D, deposited by Achen, M.G.	
	C56	Greenberg *et al.*, "Characterization of a New Megakaryocyte Cell Line: The Dami Cell," *Blood, 72(6):*1968-1977 (December, 1988).	
	C57	Gunningham, S.P., *et al.*, "The Short Form of the Alternatively Spliced flt-4 but not Its Ligand Vascular Endothelial Growth Factor C Is Related to Lymph Node Metastasis in Human Breast Cancers," *Clin. Cancer Res., 6(11)*:4278-86 (November 2000).	
	C58	Harlow *et al.*, *Antibodies: A Laboratory Manual*, pp.72-137, 141-157, 287 & 321-358 (1988).	
	C59	Hatva et al., "Expression of Endothelial Cell-Specific Receptor Tyrosine Kinases and Growth Factors in Human Brain Tumors," *Am. J. Pathol., 146*:368-378 (1995).	
	C60	Hatva, E., *et al.*, "Vascular Growth Factors and Receptors in Capillary Hemangioblastomas and Hemangiopericytomas," *Am. J. Pathol, 148(3)*:763-75 (March 1996).	
	C61	Heldin *et al.*, "Platelet-Derived Growth Factor: Mechanism of Action and Possible *in Vivo* Function," *Cell Regulation, 1*:555-566 (July, 1990).	
	C62	Hemmila *et al.*, "Europium as a Label in Time-Resolved Immunofluorometric Assays," *Annal. Biochem, 137*:335-343 (1984).	
	C63	Hewett, P.W. *et al.*, "Coexpression of *flt*-1, *flt*-4 and KDR in Freshly Isolated and Cultured Human Endothelial Cells," *Biochemical and Biophysical Research Communications, 221*:697-702 (1996).	
	C64	Hirai *et al.*, "A Novel Putative Tyrosine Kinase Receptor Encoded by the *eph* Gene," *Science, 238*:1717-1720 (1987).	
	C65	Hoogenboom, H.R., "Designing and optimizing library selection strategies for generating high-affinity antibodies," *TIBTECH, 15*:62-70 (1997).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	7	of	18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	C66	Hu, Jing-Shan, *et al.*, "A Novel Regulatory Function of Proteolytically Cleaved VEGF-2 for Vascular Endothelial and Smooth Muscle Cells," *The FASEB Journal*, 11:498-504 (May 1997).	
	C67	Huang *et al.*, "The Hematopoietic Growth Factor KL is Encoded by the *Sl* Locus and is the Ligand of the *c-kit* Receptor, the Gene Product of the W Locus," *Cell, 63*:225-33 (October 5, 1990).	
	C68	Hunter & Greenwood, "Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity," *Nature, 194(4827)*:495-496 (May 5, 1962).	
	C69	Jacquemier, J., *et al.*, "Prognosis of Breast-Carcinoma Lymphagenesis Evaluated by Immunohistochemical Investigation of Vascular-Endothelial-Growth-Factor Receptor 3," *Int. J. Cancer (Pred. Oncol.), 89*:69-73 (2000).	
	C70	Jeltsch, "Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice," *Science, 276*:1423-1425 (May 30, 1997).	
	C71	Jones, P.T. *et al.*, "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature, 321*:522-525 (May, 1986).	
	C72	Jones, A., *et al.*, "Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis," *BJU International, 86*:80-86 (2000).	
	C73	Joukov, V. *et al.*, "Proteolytic processing regulates receptor specificity and activity of VEGF-C," *EMBO Journal, 16(13)*:3898-3911 (June, 1997).	
	C74	Joukov *et al.*, "A Novel Vascular Endothelial Growth Factor, VEGF-C, is a Ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases," *EMBO J., 15(2)*:290-298 (January 15, 1996).	
	C75	Jussila, L. *et al.*, "Lymphatic Endothelium and Kaposi's Sarcoma Spindle Cells Detected by Antibodies against the Vascular Endothelial Growth Factor Receptor-3," *Cancer Res., 58*:1599-1604 (April, 1998).	
	C76	Kaipainen *et al.*, "Expression of the FMS-Like Tyrosine Kinase 4 Gene Becomes Restricted to Lymphatic Endothelium During Development," *Proc. Nat'l Acad. Sci., USA, 92*:3566-3570 (April, 1995).	
	C77	Kaipainen *et al.*, "The Related FLT4, FLT1, and KDR Receptor Tyrosine Kinases Show Distinct Expression Patterns in Human Fetal Endothelial Cells," *J. Exp. Med., 178*:2077-2088 (December, 1993).	
	C78	Karkkainen, M.J., *et al.*, "Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis," *Oncogene, 19(49)*:5598-605 (November 20, 2000).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	C79	Karkkainen, *et al.*, "Lymphatic endothelium: a new frontier of metastasis research," *Nat. Cell. Biol.* **4**:E2-E5 (2002)	
	C80	Karpanen, *et al.*, "Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth," *Cancer Res.* **61**:1786-90 (2001)	
	C81	Kerstens, H. *et al.*, "A Novel In Situ Hybridization Signal Amplification Method Based on the Deposition of Biotinylated Tyramine," *Journal Histochemistry and Cytochemistry, 43(4)*:347-352 (1995).	
	C82	Kettleborough, C.A. *et al.*, "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," Protein Engineering, 4(7):773-783 (1991).	
	C83	Kieffer *et al.*, "Uncoupling in the Expression of Platelet GP IIb/IIIa in Human Endothelial Cells and K562 Cells: Absence of Immunologic Crossreactivity Between Platelet GP IIb and the Vitronectin Receptor Alpha Chain," *Blood, 72(4):*1209-1215 (October, 1988).	
	C84	Kim, K.J. *et al.*, "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth *in vivo*," *Nature, 362(6423)*:841-844 (April, 1993).	
	C85	Koeffler *et al.*, "Acute Myelogenous Leukemia: A Human Cell Line Responsive to Colony-Stimulating Activity," *Science, 200:*1153-1154 (1978).	
	C86	Köhler *et al.*, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," *Nature, 256:*495-497 (August 7, 1975).	
	C87	Korhonen *et al.*, "Enhanced Expression of the *tie* Receptor Tyrosine Kinase in Endothelial Cells During Neovascularization," *Blood, 80(10)*:2548-2555 (November 15, 1992).	
	C88	Korhonen *et al.*, "The Mouse Tie Receptor Tyrosine Kinase Gene: Expression During Embryonic Angiogenesis," *Oncogene (England), 9(2)*:395-403 (February, 1994).	
	C89	Kozbor *et al.*, "The Production of Monoclonal Antibodies From Human Lymphocytes," *Immunology Today, 4(3):*72-79 (1983).	
	C90	Kubo, H., *et al.*, "Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis," *Blood, 96(2)*:546-553 (15 July 2000).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	C91	Kukk *et al.*, "VEGF-C Receptor Binding and Pattern of Expression with VEGFR-3 Suggests A Role in Lymphatic Vascular Development," *Development, 122*:3829-3837 (December, 1996).	
	C92	Kurebayashi, J., *et al.*, "Expression of Vascular Endothelial Growth Factor (VEGF) Family Members in Breast Cancer," *Jpn. J. Cancer Res., 90(9)*:977-81 (September 1999).	
	C93	Lee *et al.*, "Vascular Endothelial Growth Factor-Related Protein: A Ligand and Specific Activator of the Tyrosine Kinase Receptor Flt4," *Proc. Natl. Acad. Sci., USA, 93*:1988-1992 (March, 1996).	
	C94	Leu, *et al.*, "Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation," *Cancer Res.* **60**:4324-7 (2000)	
	C95	Lhotak *et al.*, "Characterization of Elk, a Brain-Specific Receptor Tyrosine Kinase," *Mol. Cell. Biol., 11*:2496-2502 (May, 1991).	
	C96	Lindberg et al. "cDNA Cloning and Characterization of *eck,* an Epithelial Cell Receptor Protein-Tyrosine Kinase in the *eph/elk* Family of Protein Kinases," *Mol. Cell. Biol., 10*:6316-6324 (December, 1990).	
	C97	Lovgren *et al.*, "Time-Resolved Fluorometry in Immunoassay," *In*: Collins W.P. (Ed.) *Alternative Immunoassays*, John Wiley & Sons Ltd., pp.203-217 (1985).	
	C98	Lozzio *et al.*, "Human Chronic Myelogenous Leukemia Cell-Line With Positive Philadelphia Chromosome," *Blood, 45(3)*:321-334 (March, 1975).	
	C99	Lyman *et al.*, "Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells," *Cell, 75*:1157-1167 (December 17, 1993).	
	C100	Lymboussaki, A. *et al.*, "Expression of the Vascular Endothelial Growth Factor C Receptor VEGFR-3 in Lymphatic Endothelium of the Skin and in Vascular Tumors," *American Journal of Pathology, 153(2)*:395-403 (August, 1998).	
	C101	Makela *et al.*, "Plasmid pLTRpoly: a Versatile High-Efficiency Mammalian Expression Vector," *Gene, 118*:293-294 (1992).	
	C102	Makinen, *et al.*, "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3," *Nat. Med.* **7**:199-205 (2001)	
	C103	Marchio, S., *et al.*, "Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma Cells," *J. Biol. Chem., 274(39)*:27617-22 (September 24, 1999).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	C104	Marconcini, L., *et al.*, "c-*fos*-induced growth factor/vascular endothelial growth factor D induces angiogenesis *in vivo* and *in vitro*," *Proc. Natl. Acad. Sci. USA, 96*:9671-76 (August 1999).	
	C105	Martin *et al.*, "HEL Cells: A New Human Erythroleukemia Cell Line With Spontaneous Induced Globin Expression," *Science, 216*:1233-1235 (1982).	
	C106	Matthews *et al.*, "A Receptor Tyrosine Kinase cDNA Isolated From a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to *c-kit*," *Proc. Natl. Acad. Sci. USA, 88(20)*:9026-9030 (October, 1991).	
	C107	Matthews *et al.*, "A Receptor Tyrosine Kinase Specific to Hematopoietic Stem and Progenitor Cell-Enriched Populations," *Cell, 65(7)*:1143-1152 (June 28, 1991).	
	C108	Mattila, *et al.*, "VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors," *Int. J. Cancer.* **98**:946-951 (2002)	
	C109	McCutchan *et al.*, "Enhancement of the Infectivity of Simian Virus 40 Deoxyribonucleic Acid with Diethylaminoethyl-Dectran," *J. Natl. Cancer Inst., 41*:351-357 (1968).	
	C110	Metzelaar *et al.*, "CD63 Antigen," *J. Biol. Chem., 266(5)*:3239-3245 (February 15, 1991).	
	C111	Mikayama T., Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor. Proc. Natl. Acad. Sci. USA Vol. 90, pages 10056-10060, 1993.	
	C112	Millauer *et al.*, "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis, *Cell, 72*:835-846 (March 26, 1993).	
	C113	Minowada *et al.*, "Brief Communication: Rosette-Forming Human Lymphoid Cell Lines: Establishment and Evidence for Origin of Thymus-Derived Lymphocytes," *J. Natl. Cancer Inst., 49*:891-895 (1972).	
	C114	Mollinedo *et al.*, "Early and Selective Induction of Apoptosis in Human Leukemic Cells By the Alkyl-Lysophospholipid ET-18-OCH_3," *Biochem. & Biophys. Res. Comm., 192(2)*:603-609 (April 30, 1993).	
	C115	Moriyama, M., *et al.*, "Immunohistochemical Study of Tumour Angiogenesis in Oral Squamous Cell Carcinoma," *Oral Oncol., 33(5)*:369-74 (September 1997).	
	C116	Moroni *et al.*, "EGF-R Antisense RNA Blocks Expression of the Epidermal Growth Factor Receptor and Suppresses the Transforming Phenotype of a Human Carcinoma Cell Line," *J. Biol. Chem., 267(5)*:2714-2722 (February 5, 1992).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/774,802
				Filing Date	February 9, 2004
				First Named Inventor	Kari Alitalo et al.
(Use as many sheets as necessary)				Art Unit	1646
				Examiner Name	To be Assigned
Sheet	11	of	18	Attorney Docket Number	28967/34891.1

	C117	Morrison, S.L. *et al.*, "Genetically Engineered Antibody Molecules," *Advances in Immunology, 44*:65-92 (1989).	
	C118	Moshakis,V. *et al.*, "Localization of human breast-carcinoma xenografts using antibodies to carcinoembryonic antigen," *Br. J. Cancer, 43*:575-581 (1981).	
	C119	Mukkala *et al.*, "The Synthesis and Use of Activated *N*-Benzyl Derivatives of Diethylenetriaminetetraacetic Acids: Alternative Reagents for Labeling of Antibodies with Metal Ions," *Annal. Biochem, 176*:319-325 (1989).	
	C120	Mustonen *et al.*, "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," *J. Cell Biology, 129(4)*:895-898 (1995).	
	C121	Nathanson, S.D., *et al.*, "Microvessels That Predict Axillary Lymph Node Metastases in Patients With Breast Cancer," *Arch Surg, 135(5)*:586-93 (May 2000).	
	C122	Nicosia, R.F., "What Is the Role of Vascular Endothelial Growth Factor-Related Molecules in Tumor Angiogenesis?" *Am. J. Pathol, 153(1)*:11-6 (July 1998).	
	C123	Niki, T., *et al.*, "Expression of Vascular Endothelial Growth Factors A, B, C, and D and Their Relationships to Lymph Node Status in Lung Adenocarcinoma," *Clin. Cancer Res., 6(6)*:2431-9 (June 2000).	
	C124	Nowell *et al.*, "Chromosome Studies in Preleukemic States: Myeloproliferative versus Cytopenic Disorders," *Cancer, 42*:2254-2260 (1978).	
	C125	Oelrichs *et al.*, "NYK/FLK-1: A Putative Receptor Protein Tyrosine Kinase Isolated From E10 Embryonic Neuroepithelium is Expressed in Endothelial Cells of the Developing Embryo," *Oncogene, 8(1)*:11-18 (January, 1993).	
	C126	Ohta, Y., *et al.*, "Increased Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor-C and Decreased NM23 Expression Associated with Microdissemination in the Lymph Nodes in Stage 1 Non-Small Cell Lung Cancer," *J. Thorac Cardiovasc Surg, 119(4 Pt 1)*:804-13 (April 2000).	
	C127	Ohta, Y., *et al.*, "VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours," *Br. J. Cancer, 81(1)*:54-61 (September 1999).	
	C128	O'Reilly, M.S. *et al.*, "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," *Cell, 79(2)*:315-328 (October, 1994).	
	C129	O'Reilly, M.S. *et al.*, "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," *Cell, 88(2)*:277-285 (January, 1997).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/774,802
				Filing Date	February 9, 2004
				First Named Inventor	Kari Alitalo et al.
(Use as many sheets as necessary)				Art Unit	1646
				Examiner Name	To be Assigned
Sheet	12	of	18	Attorney Docket Number	28967/34891.1

	C130	Oh *et al.*, "VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane," *Developmental Biology, 188*:96-109 (1997).	
	C131	Padlan, E.A., "A Possible Procedure For Reducing The Immunogenicity Of Antibody Variable Domains While Preserving Their Ligand-Binding Properties," *Molecular Immunology, 28(4/5)*:489-498 (1991).	
	C132	Pajusola *et al.*, "FLT4 Receptor Tyrosine Kinase Contains Seven Immunoglobulin-Like Loops and is Expressed in Multiple Human Tissues and Cell Lines," *Cancer Research, 52(20)*:5738-5743 (October 15, 1992).	
	C133	Pajusola *et al.*, "Two Human FLT4 Receptor Tyrosine Kinase Isoforms With Distinct Carboxy Terminal Tails are Produced by Alternative Processing of Primary Transcripts," *Oncogene, 8*:2931-2937 (1993).	
	C134	Pajusola, "Cloning and Characterization of a New Endothelial Receptor Tyrosine Kinase FLT4 and Two Novel VEGF-Like Growth Factors VEGF-B and VEGF-C," Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute and Department of Biosciences, Division of Genetics, University of Helsinki, Academic Dissertation, Helsinki 1996.	
	C135	Pajusola *et al.*, "Signalling Properties of FLT4, a Proteolytically Processed Receptor Tyrosine Kinase Related To Two VEGF Receptors," *Oncogene, 9*:3545-3555 (1994).	
	C136	Partanen *et al.*, "A Novel Endothelial Cell Surface Receptor Tyrosine Kinase with Extracellular Epidermal Growth Factor Homology Domains," *Mol. Cell. Biol., 12(4)*:1698-1707 (April, 1992).	
	C137	Partanen *et al.*, "Putative Tyrosine Kinases Expressed in K-562 Human Leukemia Cells," *Proc. Nat'l Acad. Sci., USA, 87(22)*:8913-8917 (November, 1990).	
	C138	Partanen, T.A., *et al.*, "Lack of Lymphatic Vascular Specificity of Vascular Endothelial Growth Factor Receptor 3 in 185 Vascular Tumors," *Cancer, 86(11)*:406-12 (December 1, 1999).	
	C139	Patent Cooperation Treaty Search Report for PCT/US 99/23525	
	C140	Perumov *et al.*, "Influence of Antisense RNA's of Interleukin-1β and Interleukin-1 Receptor Antagonist on Interleukin-1β Production," *J. Cell. Biochem., Supplement, 16 pt B*:285 *(ABSTRACT J216)* (1992).	
	C141	Peters *et al.*, "Vascular Endothelial Growth Factor Receptor Expression During Embryogenesis and Tissue Repair Suggests a Role in Endothelial Differentiation and Blood Vessel Growth," *Proc. Nat'l Acad. Sci., USA, 90*:8915-8919 (October, 1993).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	C142	Pietersz *et al.*, "Antibody Conjugates for the Treatment of Cancer," *Immunological Reviews, 129*:57-80 (1992).	
	C143	Plückthun, A. *et al.*, "New protein engineering approaches to multivalent and bispecific antibody fragments," *Immunotechnology, 3*:83-105 (1997).	
	C144	Poncz *et al.*, "Cloning and Characterization of Platelet Factor 4 cDNA Derived From a Human Erythroleukemic Cell Line," *Blood, 69(1)*:219-223 (January, 1987).	
	C145	Rader, C. *et al.*, "Phage display of combinatorial antibody libraries," *Curr. Opin. Biotech., 8*:503-508 (1997).	
	C146	Reedijk *et al.*, "Tyr721 Regulates Specific Binding of the CSF-1 Receptor Kinase Insert to P1 3'-Kinase SH2 Domains: a Model for SH2-Mediated Receptor-Target Interactions," *EMBO J., 11(4)*:1365-1372 (1992).	
	C147	Relf, M. *et al.*, "Expression of the Angiogenic Factors Vascular Endothelial Cell Growth Factor, Acidic and Basic Fibroblast Growth Factor, Tumor Growth Factor β-1, Platelet-derived Endothelial Cell Growth Factor, Placenta Growth Factor, and Pleiotrophin in Human Primary Breast Cancer and Its Relation to Angiogenesis," *Cancer Research, 57*:963-969 (March, 1997).	
	C148	Renner, C. *et al.*, "Tumor Therapy by Immune Recruitment with Bispecific Antibodies," *Immunological Reviews, No.145*, pp. 179-209 (1995).	
	C149	Riechmann, L. *et al.*, "Reshaping human antibodies for therapy," *Nature, 332(6162)*:323-327 (March, 1988).	
	C150	Roitt, M., "Essential Immunology," Blackwell Scientific Pub., Oxford, pp.65-68 & 74 (1991).	
	C151	Rosnet *et al.*, "Isolation and Chromosomal Localization of a Novel FMS-Like Tyrosine Kinase Gene," *Oncogene, 6(9)*:1641-1650 (1991).	
	C152	Rosnet *et al.*, "Murine *Flt3*, a Gene Encoding a Novel Tyrosine Kinase Receptor of the PDFR/CSF1R Family," *Genomics, 9*:380-385 (1991).	
	C153	Saaristo, A., *et al.*, "Vascular Endothelial Growth Factor-C and its Receptor VEGFR-3 in the Nasal Mucosa and in Nasopharyngeal Tumors," *Am. J. Pathology, 157(1)*:7-14 (July 2000).	
	C154	Sabin, F.R., "The Lymphatic System in Human Embryos, with Consideration of the Morphology of the System as a Whole," *Am. J. Anat., 9(1)*:43-91 (1909).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	C155	Salven, P. *et al.*, "Vascular Endothelial Growth Factors VEGF-B and VEGF-C Are Expressed in Human Tumors," *American J. Pathology, 153(1)*:103-108 (July, 1998).	
	C156	Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual,* Cold Spring Harbor Laboratory Press, pp. 2.60-2.70, 4.21-4.32, 7.3-7.36 (1989).	
	C157	Sato and Seiki, "Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells," *Oncogene, 8*:395-405 (1993).	
	C158	Satoh *et al.*, "Regional Localization of the Human c-*ros*-1 on 6q22 and *flt* on 13q12," *Jpn. J. Cancer Res., 78:*772-775 (1987).	
	C159	Schneider *et al.*, "A One-step Purification of Membrane Proteins Using a High Efficiency Immunomatrix," *J. Biol. Chem., 257(18)*:10766-10769 (September 25, 1982).	
	C160	Schreiber *et al.*, "Interaction of endothelial cell growth factor with heparin: Characterization by receptor and antibody recognition," *Proc. Nat'l Acad. Sci., 82*:6138-6142 (September, 1985).	
	C161	Schwenk *et al.*, "Cell Cycle Dependency of a T-Cell Marker on Lymphoblasts," *Blut, 31*:299-306 (1975).	
	C162	Scott, P.A.E. *et al.*, "Laboratory-Clinic Interface: Current approaches to targeting cancer using antiangiogenesis therapies," *Cancer Treatment Reviews, 20*:393-412 (1994).	
	C163	Segal, D.M. *et al.*, "Alternative Triggering Molecules and Single Chain Bispecific Antibodies," *Journal of Hematotherapy, 4*:377-382 (1995).	
	C164	Segal, D.M. *et al.*, "Targetting of Anti-Tumor Responses with Bispecific Antibodies," *Immunobiology, 185(2-4)*:390-402 (August, 1992).	
	C165	Sherr *et al.*, "The c-*fms* Proto-Oncogene Product is Related to the Receptor for the Mononuclear Phagocyte Growth Factor, CSF-1," *Cell, 41*:665-676 (July, 1985).	
	C166	Shi *et al.*, "16-Kilodalton Heparin Binding (Fibroblast) Growth Factor Type One Appears in a Stable 40-Kilodalton Complex After Receptor-Dependent Internalization," *J. Biol. Chem., 266(9)*:5774-5779 (March 25, 1991).	
	C167	Shibuya *et al.*, "Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosine Kinase Gene *(flt)* Closely Related to the *fms* Family," *Oncogene, 5:*519-524 (1990).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	15	of	18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	C168	Shibuya, M., "Role of VEGF-FLT Receptor System in Normal and Tumor Angiogenesis," *Advances in Cancer Research, 67*:281-316 (1995).	
	C169	Shushanov, S., *et al.*, "VEGFc and VEGFR3 Expression in Human Thyroid Pathologies," *Int. J. Cancer, 86*:47-52 (2000).	
	C170	Siemeister, *et al.*, "Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway," *Cancer Res.* **59**:3185-91 (1999)	
	C171	Skobe, M., *et al.*, "Vascular Endothelial Growth Factor-C (VEGF-C) and its Receptors KDR and flt-4 are Expressed in AIDS-Associated Kaposi's Sarcoma," *J. Invest. Dermatology, 113*:1047-1053 (1999).	
	C172	Sowter, H.M., *et al.*, "Expression and Localization of the Vascular Endothelial Growth Factor Family in Ovarian Epithelial Tumors," *Lab. Invest., 77(6)*:607-14 (December 1997).	
	C173	Stacey *et al.*, "SVpoly: a Versatile Mammalian Expression Vector," *Nucl. Acids Res., 18(9)*:2829 (1990).	
	C174	Staunton *et al.*, "The Arrangement of the Immunoglobulin-Like Domains of ICAM-1 and the Binding Sites for LFA-1 and Rhinovirus," *Cell, 61*:243-254 (April 20, 1990).	
	C175	Stenman *et al.*, "Human PDGFA Receptor Gene Maps to the Same Region on Chromosome 4 as the KIT Oncogene," *Genes, Chromosomes, Cancer, 1*:155-158 (1989).	
	C176	Sundström *et al.*, "Establishment and Characterization of a Human Histiocytic Lymphoma Cell Line (U-937)," *Int. J. Cancer, 17*:565-577 (1976).	
	C177	Swolin *et al.*, "On the 5q-Deletion: Clinical and Cytogenetic Observations in Ten Patients and Review of the Literature," *Blood, 58*:986-993 (1981).	
	C178	Tekmal, R.R. *et al.*, "A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene," *Cancer Letters, 118(1)*:21-28 (September, 1997).	
	C179	Tempest, P.R. *et al.*, "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection *in Vivo*," *BioTechnology, 9(3)*:266-271 (March, 1991).	
	C180	Terman *et al.*, "Identification of a New Endothelial Cell growth Factor Receptor Tyrosine Kinase," *Oncogene, 6(9)*:1677-1683 (1991).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/774,802
				Filing Date	February 9, 2004
				First Named Inventor	Kari Alitalo et al.
				Art Unit	1646
(Use as many sheets as necessary)				Examiner Name	To be Assigned
Sheet	16	of	18	Attorney Docket Number	28967/34891.1

	C181	Terman *et al.*, "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor," *Biochem & Biophys. Res. Comm., 187(3)*:1579-1586 (September 30, 1992).	
	C182	Thompson *et al.*, "Cloned Human Teratoma Cells Differentiate into Neuron-Like Cells and Other Cell Types in Retinoic Acid," *J. Cell Sci., 72*:37-64 (1984).	
	C183	Tomiyasu *et al.*, "Long Arm Deletion of Chromosome No. 5 in a Case of Philadelphia Chromosome-Positive Chronic Myelocytic Leukemia," *Cancer Genet. Cytogenet., 2*:309-315 (1980).	
	C184	Tortora *et al.*, "Differentiation of HL-60 Leukemia By Type I Regulatory Subunit Antisense Oligodeoxynucleotide of a cAMP-Dependent Protein Kinase," *Proc. Nat'l Acad. Sci., USA, 88(5)*:2011-2015 (March, 1991).	
	C185	Traunecker, A. *et al.*, "Myeloma based expression system for production of large mammalian proteins," *Trends in BioTechnology, 9(4)*:109-113 (April, 1991).	
	C186	Tsurusaki, T., *et al.*, "Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis," *Br. J. Cancer, 801(2)*:309-313 (1999).	
	C187	Ullrich *et al.*, "Signal Transduction By Receptors with Tyrosine Kinase Activity," *Cell, 61*:203-212 (April 20, 1990).	
	C188	Valtola, R., *et al.*, "VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer," *Am. J. Pathol., 154(5)*:1381-90 (May 1999).	
	C189	Van der Putte, S.C.J., "The Development of the Lymphatic System in Man," *Adv. Anat. Embryol. Cell Biol., 51*:3 (1975).	
	C190	Van Den Berghe *et al.*, "Distinct Haematological Disorder with Deletion of Long Arm of No. 5 Chromosome." *Nature, 251*:437-439 (1974).	
	C191	Van Den Berghe *et al.*, "Transformation of Polycythemia Vera to Myelofibrosis and Late Appearance of a 5q-Chromosome Anomaly," *Cancer Genet. Cytogenet., 1*:157-162 (1979).	
	C192	Van Hinsberg *et al.*, "Effect of Thrombin on the Production of Plasminogen Activators and PA Inhibitor-1 by Human Foreskin Microvascular Endothelial Cells," *Thromb. Haemostas., 57(2)*:148-153 (1987).	
	C193	Van Hinsberg *et al.*, "Production of Plasminogen Activators and Inhibitors by Serially Propagated Endothelial Cells From Adult Human Blood Vessels," *Arteriosclerosis, 7*:389-400 (July/August, 1987).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/774,802
				Filing Date	February 9, 2004
				First Named Inventor	Kari Alitalo et al.
(Use as many sheets as necessary)				Art Unit	1646
				Examiner Name	To be Assigned
Sheet	17	of	18	Attorney Docket Number	28967/34891.1

	C194	Verhoeyen, M. *et al.*, "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," *Science, 239*:1534-1536 (March, 1988).	
	C195	Voet, et al., Biochemistry, John Wiley & Sons, Inc., pages 126-128 and 228-234, 1990.	
	C196	Wang, "Signal Transduction in Human Hematopoietic Cells by Vascular Endothelial Growth Factor Related Protein, a Novel Ligand for the FLT4 Receptor," Blood, 90(9):3507-3515 (November, 1997).	
	C197	Warrington *et al.*, "Radiation of Hybrid Map of 13 Loci on the Long Arm of Chromosome 5," *Genomics, 11:*701-708 (1991).	
	C198	Weidner, N. *et al.*, "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma," *J. Natl. Cancer Inst., 84(24)*:1875-1887 (December, 1992).	
	C199	Wen, D. *et al.*, "New Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit," *Cell, 69*:559-572 (May 1, 1992).	
	C200	Weninger, W., *et al.*, "Expression of Vascular Endothelial Growth Factor Receptor-3 and Podoplanin Suggests a Lymphatic Endothelial Cell Origin of Kaposi's Sarcoma Tumor Cells," *Lab. Invest., 79(2)*:243-51 (February 1999).	
	C201	Whang-Peng *et al.*, "Cytogenic Studies in Patients With Myelofibrosis and Myeloid Metaplasia," *Leuk. Res., 2*:41-48 (1978).	
	C202	Wilkinson *et al.*, "Expression of the Proto-Oncogene int-1 is Restricted to Specific Neural Cells in the Developing Mouse Embryo," *Cell, 50*:79-88 (1987).	
	C203	Williams *et al.*, "The Immunoglobin Superfamily-Domains for Cell Surface Recognition," *Ann. Rev. Immunol., 6*:381-405 (1988).	
	C204	Williams, J.C. *et al.*, "*N*-methyl-*N*-nitrosourea-Induced Rat Mammary Tumors. Hormonal Responsiveness but Lack of Spontaneous Metastasis," *J. Nat. Cancer Inst., 66(1)*:147-155 (January, 1981).	
	C205	Witmer, *et al.*, "VEGFR-3 in adult angiogenesis," *J. Path.* **195**:490-497 (2001)	
	C206	Witzenbichler, B., *et al.*, "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," *American Journal of Pathology*, Vol. 153, No.2:381-394 (August 1998).	
	C207	Yamaguchi *et al.*, "*Flk-1*, an *Flt*-Related Tyrosine Kinase is an Early Marker for Endothelial Cell Precursors," *Development., 118*:489-498 (1993).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 18 of 18

Complete if Known	
Application Number	10/774,802
Filing Date	February 9, 2004
First Named Inventor	Kari Alitalo et al.
Art Unit	1646
Examiner Name	To be Assigned
Attorney Docket Number	28967/34891.1

	C208	Yarden *et al.*, "Human Proto-Oncogene c-kit: A New Cell Surface Receptor Tyrosine Kinase for an Unidentified Ligand," *EMBO J., 6(11)*:3341-3351 (1987).	
	C209	Ylänne *et al.*, "Platelet Glycoprotein IIb/IIIa Complex in Cultured Cells: Localization in Focal Adhesion Sites in Spreading HEL Cells," *Blood, 72:* 1478-1486 (1988).	
	C210	Yokoyama, Y., *et al.*, "Prognostic Significance of Vascular Endothelial Growth Factor and Its Receptors in Endometrial Carcinoma," *Gyn. Oncology 77*:413-418 (2000).	
	C211	Yonemura, Y., *et al.*, "Role of Vascular Endothelial Growth Factor C Expression in the Development of Lymph Node Metastasis in Gastric Cancer," *Clin. Cancer Res., 5*:1823-1829 (July 1999).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	